Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993668 · ClinicalTrials.gov registry record · Phase 4
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
A Phase 4 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 224
- Enrollment target
NCT00993668 is a Phase 4 study that has completed, run by UCB Pharma. The registered enrollment target is 224 participants.
The verdict
NCT00993668, a Phase 4 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 224 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines, respectively.
Interventions
- OTHER Placebo
- BIOLOGICAL Certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00993668
The ClinicalTrials.gov registry entry for NCT00993668 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00993668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00993668 about?
NCT00993668 is a clinical study titled "Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines". The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines, respectively.
What is the current status of trial NCT00993668?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 224 participants. The study started on 2009-09. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00993668?
The interventions under investigation include: Placebo (OTHER), Certolizumab pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT00993668?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.